FDA unconvinced by Sanofi’s Zynquista in type 1 diabetesSanofi’s hopes of getting its dual SGLT inhibitor sotagliflozin approved alongside insulin for type 1 diabetes in the Share XFDA unconvinced by Sanofi’s Zynquista in type 1 diabeteshttps://pharmaphorum.com/news/fda-unconvinced-by-sanofis-zynquista-in-type-1-diabetes/
Sanofi/Lexicon’s sotagliflozin filed in US and EU for type 1 diabetesRegulators in the US and Europe are to review Sanofi/Lexicon’s sotagliflozin in type 1 diabetes, a potential blockbuster Share XSanofi/Lexicon’s sotagliflozin filed in US and EU for type 1 diabeteshttps://pharmaphorum.com/news/sanofi-lexicons-sotagliflozin-filed-us-eu-type-1-diabetes/
